Activity of Compounds in Sargassum sp. as Anti-atherosclerosis with Ligand-Receptor Comparison HMG-CoA Reductase- Simvastatin (1HW9) and In-Silico Toxicity Test
DOI:
https://doi.org/10.35814/jifi.v17i1.557Keywords:
docking, anti-atherosclerosis, brown seaweed, molegroAbstract
Introduction:Sargassum.sp is one of the marine biota published as antiaterosclerosis, but compound toxicity data need to be explored for safety.
Method: Virtual screening has been done with MVD software from active compounds contained in sargassum where has activity as antiaterosclerosis with the mechanism of hypolipidemic effects. Test compounds in sargassum include: fucoidan, rhamnose, fucose, galactose, fucoxantin, alginate, phlorofucofuroeckol A, phloroglucinol, phlorotannin, with HMG-COA Reductase-Simvastatin adenosine receptors with a 1HW9 /PDB code. Its toxicity is predicted using pkCSM (online).
Results: The value RS, RMSD value as a result of the docking simulation carried out on said compounds, the following results are obtained: fucoidan (-110,420; 1,478), rhamnose (-72,081; 1,629), fucose (-98,408; 1,546), galactose (-95,757; 5,187), fucoxantin (-106,297; 2,161), alginate (-84,674; 2,897), phlorofucofuroeckol A (-106.701; 2,809), phloroglucinol (-103,140; 2,142), phlorotannin (-48,826; 7,750). The prediction results of toxicity showed fucoidan, rhamnose, fucose, galactose, fucoxantin, alginate, phlorofucofuroeckol A, phloroglucinol and phlorotannin not toxic with LD50 0.95-2.482g / kg.
Conclusion:Based on RS values, fucoidan, fucoxantin and phlorofucofuroeckol A compounds contained in brown seaweed were predicted to have activity as antiaterosclerosis. Compounds in brown seaweed can also be predicted to be relatively non-toxic with a value of LD50 0.95-2.482g / kg.
References
Downloads
Published
Issue
Section
License
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















